Neurocrine Biosciences
NBIX
143.47
-2.04
-1.40%
Neurocrine Biosciences
US · NBIX
#1162 by market cap
Listed 1970
143.47
-2.04
-1.40%
Live - 5344 symbols - heartbeat 116s ago
· 2026-10-08 04:01
Pre-market
143.47
0.00%
After-hours
143.47
0.00%
Overnight
143.47
0.00%
- Market cap
- 14.58B
- P/E (TTM)i
- 20.98
- P/Bi
- 3.95
- EPSi
- 4.67
- Div yieldi
- 0.00%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on NBIX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 8.02, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +21.45% YoY
Margins
- Gross margin
- 98.18%
- Operating margin
- 22.25%
- Net margin
- 16.73%
Key ratios & quality
- PEG ratioi
- 0.46
- Altman Z-Scorei
- 8.02
PEG uses trailing P/E against the 3-year net income growth rate (45.77%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 451.20M | 788.10M | 1.05B | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B |
| Gross profit | 446.30M | 780.70M | 1.04B | 1.12B | 1.47B | 1.85B | 2.32B | 2.81B |
| Selling & admin expenses | 248.90M | 354.10M | 433.30M | 583.30M | 752.70M | 887.60M | 1.01B | 1.16B |
| Research & development | 155.80M | 200.00M | 275.00M | 328.10M | 463.80M | 565.00M | 731.10M | 1.02B |
| Operating profit | 41.60M | 226.60M | 327.50M | 207.80M | 249.00M | 394.80M | 583.00M | 636.50M |
| Pretax profit | 21.80M | 46.50M | 106.70M | 101.40M | 213.90M | 332.10M | 486.00M | 705.40M |
| Tax | 700.00K | 9.50M | -300.60M | 11.80M | 59.40M | 82.40M | 144.70M | 226.80M |
| Net profit | 21.10M | 37.00M | 407.30M | 89.60M | 154.50M | 249.70M | 341.30M | 478.60M |
| Basic EPS | 0 | 0 | 4 | 1 | 2 | 3 | 3 | 5 |
| Diluted EPS | 0.22 | 0.39 | 4.16 | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 572.60M | 687.50M | 794.90M | 805.50M | 814.50M | 959.00M |
| Gross profit | 563.40M | 677.20M | 780.90M | 787.90M | 800.70M | 935.80M |
| Selling & admin expenses | 276.50M | 286.30M | 291.60M | 301.80M | 318.50M | 439.70M |
| Research & development | 263.20M | 244.30M | 250.00M | 258.20M | 296.20M | 326.70M |
| Operating profit | 23.70M | 145.60M | 239.30M | 227.90M | 186.00M | 153.00M |
| Pretax profit | 14.70M | 159.50M | 291.80M | 239.40M | 246.80M | 162.20M |
| Tax | 6.80M | 52.00M | 82.30M | 85.70M | 48.90M | 17.80M |
| Net profit | 7.90M | 107.50M | 209.50M | 153.70M | 197.90M | 144.40M |
| Basic EPS | 0 | 1 | 2 | 2 | 2 | 1 |
| Diluted EPS | 0.08 | 1.06 | 2.04 | 1.48 | 1.91 | 1.39 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 737.78M | 831.00M | 1.02B | 972.80M | 1.45B | 1.61B | 1.72B | 2.52B |
| Cash & ST investments | 650.91M | 670.50M | 801.00M | 711.30M | 989.30M | 1.03B | 1.08B | 1.48B |
| Inventory | 10.86M | 17.30M | 28.00M | 30.50M | 35.10M | 38.30M | 57.40M | 69.00M |
| Total assets | 993.15M | 1.31B | 1.73B | 2.07B | 2.37B | 3.25B | 3.72B | 4.63B |
| Total current liabilities | 88.23M | 565.30M | 186.50M | 245.80M | 537.70M | 654.80M | 507.70M | 743.40M |
| Short-term debt | -- | 408.80M | -- | -- | 169.40M | 170.10M | -- | -- |
| Long-term debt | 388.50M | -- | 317.90M | 335.10M | -- | -- | -- | -- |
| Total liabilities | 512,386,000.00 | 669,100,000.00 | 608,500,000.00 | 698,500,000.00 | 660,900,000.00 | 1,019,400,000.00 | 1,129,000,000.00 | 1,378,400,000.00 |
| Total equity | 480.77M | 636.90M | 1.13B | 1.37B | 1.71B | 2.23B | 2.59B | 3.25B |
| Retained earnings | -1.18B | -1.13B | -725.40M | -635.80M | -406.80M | -157.10M | 29.20M | 447.70M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.64B | 1.75B | 2.16B | 2.52B | 2.44B | 1.64B |
| Cash & ST investments | 943.50M | 975.60M | 1.11B | 1.48B | 1.32B | 389.80M |
| Inventory | 59.10M | 56.90M | 69.30M | 69.00M | 64.50M | 104.20M |
| Total assets | 3.69B | 3.89B | 4.27B | 4.63B | 4.91B | 5.36B |
| Total current liabilities | 522.90M | 546.30M | 638.00M | 743.40M | 831.70M | 874.50M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,152,000,000.00 | 1,195,500,000.00 | 1,262,100,000.00 | 1,378,400,000.00 | 1,498,800,000.00 | 1,665,500,000.00 |
| Total equity | 2.54B | 2.69B | 3.00B | 3.25B | 3.41B | 3.69B |
| Retained earnings | -5.30M | 84.50M | 294.00M | 447.70M | 589.60M | 724.00M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 101.40M | 147.00M | 228.50M | 256.50M | 339.40M | 389.90M | 595.40M | 782.70M |
| Depreciation & amortization | 4.00M | 7.40M | 8.60M | 10.90M | 15.60M | 21.30M | 27.10M | 30.10M |
| Free cash flow | 76.60M | 132.30M | 217.60M | 233.10M | 322.90M | 361.60M | 557.20M | 748.70M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -300.00M | -167.70M |
| Ending cash balance | 147.20M | 115.50M | 190.30M | 344.00M | 270.70M | 259.10M | 241.00M | 721.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 64.80M | 102.00M | 227.50M | 388.40M | 145.80M | 136.40M |
| Depreciation & amortization | 7.60M | 7.30M | 7.70M | 7.50M | 7.30M | 24.80M |
| Free cash flow | 54.10M | 89.50M | 214.30M | 390.80M | 136.70M | 128.60M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -150.00M | -17.70M | 0 | 0 | -54.00M | -12.00M |
| Ending cash balance | 202.10M | 272.00M | 348.20M | 721.00M | 274.50M | 338.90M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 4.95 | 6.62 | 46.20 | 7.17 | 10.03 | 12.68 | 14.16 | 16.38 |
| ROA %i | 2.33 | 3.22 | 26.79 | 4.71 | 6.96 | 8.89 | 9.79 | 11.46 |
| ROIC %i | 6.28 | 5.18 | 38.13 | 6.70 | 8.07 | 10.93 | 13.24 | 12.43 |
| 5-year avg ROE %i | -27.92 | -19.24 | -4.38 | 4.69 | 14.99 | 16.54 | 18.05 | 12.08 |
| EBIT margin %i | 11.61 | 9.96 | 13.34 | 11.22 | 14.85 | 17.84 | 26.01 | 22.25 |
| FCF / sales %i | 16.96 | 17.42 | 20.81 | 20.56 | 21.69 | 19.16 | 23.66 | 26.17 |
| Current ratioi | 8.36 | 1.47 | 5.45 | 3.96 | 2.70 | 2.45 | 3.40 | 3.39 |
| Quick ratioi | 8.03 | 1.41 | 5.14 | 3.65 | 2.49 | 2.25 | 3.06 | 2.92 |
| Debt / assetsi | 39.12 | 37.94 | 23.77 | 21.25 | 11.10 | 13.18 | 12.24 | 8.97 |
| LT debt / equityi | 80.81 | 13.61 | 36.61 | 32.05 | 5.47 | 11.57 | 17.57 | 12.77 |
| Interest coveragei | 1.72 | 2.46 | 4.25 | 4.93 | 31.13 | 73.20 | 4.84 | -- |
| Revenue CAGR (3Y) %i | 183.66 | 274.54 | 86.35 | 35.94 | 23.62 | 21.74 | 27.61 | 24.32 |
| Net income CAGR (3Y) %i | -- | -- | -- | 61.94 | 61.03 | -15.05 | 56.17 | 45.77 |
| FCF CAGR (3Y) %i | -- | -- | -- | 44.91 | 34.64 | 18.45 | 33.71 | 32.36 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.43 | 13.39 | 14.96 | 16.38 | 22.50 | 22.09 |
| ROA %i | 8.54 | 9.68 | 10.97 | 11.46 | 15.56 | 15.26 |
| ROIC %i | 10.88 | 11.81 | 13.37 | 12.43 | 19.67 | 19.52 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 22.01 | 21.06 | 21.74 | 22.25 | 25.75 | 25.91 |
| FCF / sales %i | 20.40 | 21.06 | 22.11 | 26.17 | 26.80 | 25.80 |
| Current ratioi | 3.13 | 3.20 | 3.38 | 3.39 | 2.93 | 1.87 |
| Quick ratioi | 2.79 | 2.88 | 2.89 | 2.92 | 2.51 | 1.46 |
| Debt / assetsi | 12.13 | 11.29 | 10.04 | 8.97 | 8.28 | 7.50 |
| LT debt / equityi | 17.65 | 16.30 | 14.26 | 12.77 | 11.92 | 10.88 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- INGREZZA net product sales is the largest reported line at 74.71% of revenue, across 4 reported segments.
- The next-largest line, CRENESSITY net product sales, is a distant second at 19.13% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
INGREZZA net product sales74.71%
CRENESSITY net product sales19.13%
VYKAT XR net product sales5.66%
Other revenues0.49%
Quote time 2026-10-08 04:01:04 · For reference only, not investment advice and not tailored to your situation.